Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours

NCT04958226 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04958226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04958226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
October 15, 2021
Completion date
February 15, 2023
Enrollment
21 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumour